Date : June 2024
The global generic drugs market size was valued at USD 464.98 billion in 2023 and is projected to hit around USD 776.78 billion by 2033, growing at a CAGR of 5.2% over the forecast period from 2024 to 2033.
Here are some insights about generic drugs market
Viatris Inc.
Headquarter: USA
Telephone: +1 724-514-1800
Website: www.viatris.com
Company Shanpshot: Viatris Inc.
| Snapshot | Description |
| Year Of Inception | 2020 |
| Primary Business | Pharmaceuticals, Generics, Biosimilars, Anesthesia & Pain Management, CNS, Cardiovascular, Dermatology, Diabetes & Metabolism, Gastroenterology, Infectious Disease, Oncology, Respiratory & Allergy, Women's Healthcare, Oral Solid Doses, Complex Products, API, Healthcare, and Healthcare Solutions |
| Geographical Presence | North America, Europe, Asia Pacific, and RoW |
| Strategic Moves | Product Approval |
Viatris Inc. is a global healthcare firm founded in November 2020 by the merger of Mylan and Upjohn. It aims to empower people around the world to live healthier lives at every stage of life. Viatris seeks to provide improved access to inexpensive, high-quality medications for patients worldwide, regardless of region or circumstance, by combining the assets of these two businesses. Viatris combines industry-leading commercial, R&D, regulatory, manufacturing, legal, and medical skills with a strong commitment to quality and an unrivaled worldwide footprint to provide high-quality medications to patients in over 165 countries and territories.
Viatris has over 1,400 approved compounds across a broad spectrum of therapeutic areas, including globally renowned iconic and key brands, generics, complex generics, and biosimilars. Viatris manufactures oral solid dosages, injectable, complicated dosage forms, and APIs at roughly 50 manufacturing sites across the world. Viatris is based in Pittsburgh, Pennsylvania, with global offices in Shanghai, China, and Hyderabad, India.
Developed Markets, Greater China, JANZ, and Emerging Markets are just a few of the markets and geographies covered by Viatris. This strategy represents the Company's commitment to making its large and diverse portfolio of branded, complicated generics, and generic medicines available to people in markets around the world. The operations in North America and Europe fall under the Developed Markets sector. China, Taiwan, and Hong Kong are all part of the Greater China division. Their JANZ sector includes Japan, Australia, and New Zealand activities. The Emerging Markets sector includes the Company's ARV franchise as well as activities in countries with developing markets and emerging economies, including Asia, the Middle East, South, and Central America, Africa, and Eastern Europe.
Abbott
Headquarter: United States
Telephone: (224) 667-6100
Website: www.abbott.com
Company Shanpshot: Abbott
| Snapshot | Description |
| Year Of Inception | 1888 |
| Primary Business | Nutrition, Diagnostics, Medical Devices, and Branded Generic Pharmaceuticals |
| Geographical Presence | North America, Europe, Asia Pacific, and RoW |
| Strategic Moves | Approval and Agreement |
Abbott Laboratories is a worldwide medical device and healthcare corporation based in Abbott Park, Illinois, United States. Abbott's main business is the research, development, manufacturing, and distribution of a wide range of healthcare products. Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices are the four reportable segments for Abbott.
The Established Pharmaceutical Products segment encompasses a broad range of branded generic medications made around the world and marketed and sold in emerging markets outside of the United States. Depending on the market covered, Abbott-owned distribution centers and public warehouses sell these items directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers. Certain products are co-marketed or co-promoted with other companies or are licensed from them.
The Diagnostic Products segment contains a diverse range of diagnostic systems and tests that are produced, marketed, and sold around the world. Abbott-owned distribution centers, public warehouses, and third-party distributors typically market and sell these products directly to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic companies.
The Nutritional Products segment encompasses a vast range of pediatric and adult nutritional items that are developed, marketed, and sold all over the world. Abbott-owned distribution centers or third-party distributors advertise and sell these items directly to customers, institutions, wholesalers, retailers, health care facilities, government organizations, and third-party distributors.
The Medical Devices segment includes a wide range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, diabetes care products for diabetics, and neuromodulation devices for the management of chronic pain and mobility disorders. Medical gadgets are produced, marketed, and sold all over the world. Medical devices are generally marketed and sold directly to wholesalers, hospitals, ambulatory surgical centers, physicians' offices, and distributors from Abbott-controlled distribution centers and public warehouses in the United States, depending on the product. Depending on the market covered, sales are conducted directly to customers or through distributors outside of the United States.
Novartis AG
Telephone: +41 61 324 11 11
Website: www.novartis.com
Company Shanpshot: Novartis AG
| Snapshot | Description |
| Year Of Inception | 1996 |
| Primary Business | Research, Innovation, Quality, Sustainability, innovative medicines, generic medicines and biosimilars, global leader in eye care, unique portfolio focuses & broad healthcare portfolio, Cell & Gene Therapy, and Data & Digital |
| Geographical Presence | Americas, Europe, Middle East & Africa, and Asia Pacific |
| Strategic Moves | Product Launch and Acquisition |
Novartis AG, based in Basel, Switzerland, is a worldwide pharmaceutical corporation. It is one of the world's major pharmaceutical corporations. In March 1996, Ciba-Geigy and Sandoz merged, forming Novartis, a separate company with pharmaceutical and agrochemical operations. Other Ciba-Geigy and Sandoz industries were sold or spin off as separate firms, such as Ciba Specialty Chemicals. After a three-year hiatus, the Sandoz brand reappeared in 2003, when Novartis merged its generic medicine businesses into a single unit and renamed it, Sandoz. With the spinout of Syngenta in conjunction with AstraZeneca in 2000, Novartis divested its pesticide and genetically modified crops businesses. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, they use innovative science and digital technologies to create transformative treatments in areas of great medical need. In their quest to find new medicines, the company consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and they are finding innovative ways to expand access to their latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world.
The Sandoz Division of the corporation is a global leader in generic pharmaceuticals and biosimilars, pioneering unique techniques to help people access high-quality medications all around the world. Sandoz is the only generics firm in the top three in all major regions of the world, reaching over 500 million people annually and helping healthcare systems save money around the world. They have over 1,000 molecules covering a wide range of therapeutic areas and are a renowned pioneer in antimicrobials with over 150 product and technology combinations.
Teva Pharmaceutical Industries Ltd.
Headquarter: Israel
Telephone: 91-22-2570-5681
Website: www.tevapharm.com
Company Shanpshot: Teva Pharmaceutical Industries Ltd.
| Snapshot | Description |
| Year Of Inception | 1901 |
| Primary Business | Generic medicines, specialty medicines, CNS, active pharmaceutical ingredients, respiratory, biosimilars, biologics, pain care, migraine, and oncology |
| Geographical Presence | North America, Europe, International Market |
| Strategic Moves | Product Launch |
Teva Pharmaceutical Industries Ltd., also known as Teva Pharmaceuticals, is an Israeli pharmaceutical firm based in Petah Tikva. Its primary business is generic medications, but it also deals in active pharmaceutical ingredients and, to a lesser extent, patented pharmaceuticals. Teva Pharmaceuticals was the world's second-largest generic medicine manufacturer and eighth-largest pharmaceutical firm in 2020. Teva has facilities in Israel, the United States, Europe, Australia, and South America. The Tel Aviv Stock Exchange is where Teva shares are traded. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
The company operates through three business segments: North America, Europe, and International Markets. Each of these segments manages the company’s entire product portfolio in that region, including generics, specialty, and over-the-counter (OTC) products.
Pfizer Inc.
Headquarter: United States
Telephone: 1-800-879-3477
Website: www.pfizer.com
Company Shanpshot: Pfizer Inc.
| Snapshot | Description |
| Year Of Inception | 1942 |
| Primary Business | Therapeutic area business segment which includes vaccines, oncology, internal medicine, inflammation and immunology, rare disease |
| Geographical Presence | North America, Europe, Asia Pacific, RoW |
| Strategic Moves | Acquisition and Product Launch |
Pfizer Inc. is a global biopharmaceutical corporation founded on research. Through the research, development, manufacture, marketing, sales, and distribution of biopharmaceutical products around the world, they apply science and our global resources to offer cures to people that extend and dramatically improve their lives. They work to promote wellness, prevention, treatments, and cures for the world's most feared diseases in developed and emerging economies. They work with healthcare professionals, governments, and local communities all around the world to support and expand access to safe, affordable healthcare.
In 2020, the company operated commercial activities with a global organization that included two businesses—Biopharma and Upjohn, which were each directed by a single manager until November 16, 2020. Pfizer concluded the spin-off and merging of the Upjohn Business with Mylan on November 16, 2020. The company currently operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products around the world as a result of the combination.
Sun Pharmaceutical Industries Limited
Headquarter: Mumbai
Telephone: (+91 22) 4324 4324
Website: www.sunpharma.com
Company Shanpshot: Sun Pharmaceutical Industries Limited
| Snapshot | Description |
| Year Of Inception | 1983 |
| Primary Business | Formulations, API, US Generics, Speciality brands, and Technically complex formulations |
| Geographical Presence | North America, South America, Asia Pacific, Europe, Africa, Oceania, and CIS |
| Strategic Moves | Acquisition and Product Launch |
Sun Pharmaceutical Industries Limited is a Mumbai-based Indian multinational pharmaceutical firm that develops and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Sun Pharma has a global presence in more than 100 countries. Psychiatry, anti-infectives, neurology, cardiology, orthopedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental, and nutrition are among the therapeutic categories covered by the goods. Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budesonide, and Carvedilol.
Top Companies Include in the Generic Drugs Market:
